The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 4 1759-1764
Copyright © 2001 by The Endocrine Society
Glucagon-Like Peptide 21
Daniel J. Drucker2
Department of Medicine, Banting and Best Diabetes Centre, Toronto
General Hospital, University of Toronto, Toronto, Ontario, Canada M5G
2C4
Address correspondence and requests for reprints to: Dr. D. J. Drucker, Toronto General Hospital, 101 College Street CCRW3-845, Toronto, Ontario, Canada M5G 2C4. E-mail: d.drucker{at}utoronto.ca
 |
Abstract
|
|---|
Glucagon-like peptide 2 (GLP-2) is a 33 amino acid peptide-encoded
carboxyterminal to the sequence of GLP-1 in the
proglucagon gene. Both GLP-1 and GLP-2 are secreted from
gut endocrine cells and promote nutrient absorption through distinct
mechanisms of action. GLP-2 regulates gastric motility, gastric acid
secretion, intestinal hexose transport, and increases the barrier
function of the gut epithelium. GLP-2 significantly enhances the
surface area of the mucosal epithelium via stimulation of crypt cell
proliferation and inhibition of apoptosis in the enterocyte and crypt
compartments. The cytoprotective and reparative effects of GLP-2 are
evident in rodent models of experimental intestinal injury. GLP-2
reduces mortality and decreases mucosal injury, cytokine expression,
and bacterial septicemia in the setting of small and large bowel
inflammation. GLP-2 also enhances nutrient absorption and gut
adaptation in rodents or humans with short bowel syndrome. The actions
of GLP-2 are transduced by the GLP-2 receptor, a G protein-coupled
receptor expressed in gut endocrine cells of the stomach, small bowel,
and colon. Activation of GLP-2 receptor signaling in heterologous cells
promotes resistance to apoptotic injury in vitro. The
cytoprotective, reparative, and energy-retentive properties of GLP-2
suggests that GLP-2 may potentially be useful for the treatment of
human disorders characterized by injury and/or dysfunction of the
intestinal mucosal epithelium.
|
Introduction
|
|---|
THE GLUCAGON-LIKE PEPTIDES (GLPs) are
produced in open type gut endocrine cells of the small and large
intestine and play diverse roles in the regulation of energy
homeostasis. Food ingestion sets in motion coordinated peptidergic
responses that regulate nutrient transit through the gut, and nutrient
absorption. Gut peptides also contribute to optimization of mucosal
epithelial function for nutrient digestion and absorption. Following
nutrient absorption into the blood stream, enteroendocrine-derived
peptides such as GLP-1 facilitate nutrient disposal by
regulating islet hormones and, indirectly, energy absorption via
effects on liver, muscle, and adipose tissue. The aim of this review is
to highlight recent advances in our understanding of the role played by
GLP-2 in the regulation of intestinal epithelial biology and nutrient
absorption.
The sequence of proglucagon contains a number of distinct peptides with
pleiotropic actions, including glicentin, glucagon, oxyntomodulin, and
two GLPs as well as two intervening or spacer peptides (Fig. 1
). Whereas glucagon, GLP-1,
and GLP-2 exert well-defined actions through known receptors, the
biological actions of the remaining proglucagon-derived peptides remain
less well characterized. Furthermore, no receptors have yet been
isolated for glicentin, oxyntomodulin, or the intervening peptides
(1, 2, 3, 4).
View larger version (33K):
[in this window]
[in a new window]
|
Figure 1. Structure of mammalian proglucagon, the
proglucagon-derived peptides, and the biological actions of GLP-2. The
numbers above and below the proglucagon
molecule correspond to the positions and length of specific PGDPs.
MPGF, Major proglucagon fragment; IP, intervening peptide.
|
|
Although the sequence of GLP-2 was not detected in anglerfish islet
proglucagon complementary DNAs (cDNAs; Ref. 5), the GLP-2
sequence (Fig. 2) was detected in all
isolated mammalian proglucagon cDNAs and genes (6, 7, 8, 9, 10) as
a 33 amino acid peptide located carboxyterminal to GLP-1
and intervening peptide 2 (Figs. 1
and 2). Subsequent studies
demonstrated that fish, chickens, and lizards generate GLP-2 in the gut
as a result of tissue-specific alternative RNA splicing of proglucagon
RNA transcripts (11, 12). In mammals, tissue-specific
posttranslational processing liberates GLP-2 from proglucagon in the
intestine and brain but not in pancreas, as a result of cell-specific
expression of prohormone convertases in gut endocrine cells
(13). Isolation and sequencing of GLP-2 from the porcine
and human intestine confirmed that GLP-2 is a 33 amino acid peptide
(Fig 2), corresponding to proglucagon 126–158, ending in a
carboxyterminal Asp residue (14, 15).
View larger version (12K):
[in this window]
[in a new window]
|
Figure 2. Peptide sequences of human glucagon,
GLP-1, and GLP-2. Amino acids common to all three peptides
are shown in bold. Amino acids common to glucagon and
GLP-1, GLP-1, and GLP-2, and glucagon and
GLP-2 are shown in green, blue, and
red, respectively.
|
|
Initial studies of GLP-2 biological activity demonstrated increased
adenylate cyclase activity in rat hypothalamic and pituitary membrane
preparations following incubation with 50 pM GLP-2
(16). Subsequent analyses of GLP-2 activity in the gut
either failed to demonstrate activity of GLP-2 or demonstrated
GLP-2-mediated inhibition of serum-stimulated intestinal cell growth
in vitro (17). Nevertheless, despite these
negative findings, considerable experimental evidence correlated
increased expression and secretion of intestinal proglucagon-derived
peptides (PGDPs) with bowel injury and mucosal growth of the small
intestine (18, 19, 20, 21, 22). Furthermore, two patients with
glucagonomas exhibited marked small bowel villus hyperplasia that was
reversed following surgical removal of the tumor (23, 24).
Following observations that mice with sc glucagonomas developed massive
small bowel hyperplasia, peptide injection studies identified GLP-2 as
the PGDP with significant intestinotrophic activity
(25).
|
GLP-2 synthesis, secretion, and degradation
|
|---|
A single proglucagon messenger RNA (mRNA) transcript, identical in
sequence to proglucagon mRNAs in pancreas and brain (Fig. 1), is
expressed in the mammalian small and large intestine
(26, 27, 28). GLP-1 and GLP-2 are cosecreted from
the gut (29) with the type and amount of nutrient
ingestion representing a primary determinant of both intestinal
proglucagon gene expression (30, 31, 32, 33) and GLP-2 secretion
in rodent, pig, and human studies (34, 35, 36, 37). Fiber-enriched
diets and fatty acids are potent stimulators of GLP-2 secretion in
rodents and human subjects (36, 38).
Intestinal injury or resection is associated with increased levels of
proglucagon mRNA transcripts in the intestinal remnant as a result of
an increase in proglucagon RNA content in the remaining enteroendocrine
cells (39, 40, 41, 42). The kidney seems to be an important
determinant of GLP-2 clearance as levels of immunoreactive GLP-2 are
increased in human patients with renal failure (43).
Similarly, experimental nephrectomy results in delayed clearance and
increased circulating levels of GLP-2 in rats (44, 45).
The estimated elimination t1/2 of exogenously
administered GLP-2 in human studies seems to be 
7.2 min
(46), considerably longer than the
t1/2 of GLP-1 in similar
studies.
Analysis of rat and human plasma using a combination of
high-performance liquid chromatography and site-specific GLP-2 antisera
reveals the presence of two principal circulating molecular forms,
GLP-21–33 and GLP-23–33
(15, 35, 46, 47). GLP-1, gastric inhibitory
peptide, and GLP-2 all contain an alanine residue in position 2,
rendering them ideal substrates for degradation by dipeptidyl peptidase
IV (DP IV), a ubiquitous protease expressed in the gut and vascular
endothelium (48, 49). Incubation of GLP-2 with DP IV
in vitro results in cleavage to the bioinactive
GLP-23–33 peptide, and inhibitors of DP IV
prevent GLP-2 degradation both in vitro and in
vivo (35, 46, 47). The importance of DP IV for the
biological activity of GLP-2 is exemplified by studies in rats
demonstrating considerably greater intestinotrophic activity of an
exogenously administered GLP-2 analog resistant to DP IV-mediated
inactivation (47). Similarly coadministration of a DP IV
inhibitor potentiates the trophic activity of exogenous native GLP-2 in
rats (50).
Increased circulating levels of GLP-2 are associated with the
development of intestinal mucosal hyperplasia in rodents with
experimental diabetes (38, 51). Administration of insulin
to diabetic rats reduces the levels of circulating GLP-2 and reverses
the small bowel mucosal hyperplasia (51). Human subjects
with inflammatory bowel disease exhibit normal to increased levels of
circulating bioactive GLP-21–33
(52), attributable in part to a decrease in levels of
circulating DP IV activity. Patients with Crohn’s disease and marked
involvement of the terminal ileum and patients with short bowel
syndrome and lack of a colon in continuity with the remnant small bowel
exhibit deficient levels of circulating GLP-2 and reduced
meal-stimulated GLP-2 secretion, respectively (52, 53). In
contrast, patients with ileal resection but a preserved colon exhibit
increased fasting and meal-stimulated levels of GLP-2 and enhanced
intestinal adaptation (54), providing a possible
physiological explanation linking the presence of a colon with
facilitated intestinal adaptation.
|
Biological activities of GLP-2
|
|---|
The gastrointestinal tract, from the stomach to the colon, is the
principal target for GLP-2 action. GLP-2 inhibits stimulated gastric
acid secretion in human subjects and reduces antral gastric motility in
the pig (55, 56). Acute GLP-2 infusion rapidly increases
intestinal hexose transport in rats, with significant increases in both
hexose and SGLT-1 transport activity detectable within 60 min after
initiation of iv GLP-2 infusion (57, 58). Administration
of GLP-2 to normal mice produces significant increases in intestinal
barrier function. Reduced epithelial permeability as measured by
decreased ion and macromolecule transport, is detectable in Ussing
chamber studies after a single injection of GLP-2 (59).
Morphologically, intestinal epithelial cells appear narrower and
longer, with increased numbers of longer microvilli detectable on the
luminal surface of the enterocyte following several days of GLP-2
administration (59).
GLP-2 administered exogenously to mice and rats promotes expansion of
the mucosal epithelium in the small and large bowel, with the most
prominent trophic effects seen in the small bowel, specifically in the
jejunum (25, 60). The trophic effects of GLP-2 are
independent of the route of GLP-2 administration and are observed after
iv, sc, or ip GLP-2 administration (57, 60, 61, 62). Although
the optimal dosing and timing of GLP-2 administration for human
clinical studies remains to be determined, GLP-2 is intestinotrophic in
rodents even in daily or every other day administration regimens
(60, 61). Whereas small changes in intestinal length have
been detected after GLP-2 treatment (63), increased
thickness of the intestinal mucosa, predominantly an increase in small
bowel villus height and mucosal surface area, is invariably detected
after several days of GLP-2 treatment (25, 47, 60, 61, 63). Enhanced thickness of the mucosal epithelium may be
explained by GLP-2-stimulated increases in crypt cell proliferation,
coupled with a decrease in the rate of enterocyte apoptosis (25, 61).
The GLP-2-treated bowel is functionally normal as assessed by analysis
of macromolecule expression, and normal levels of mucosal enzymes are
observed in the GLP-2-treated murine intestine (64).
Absorption of carbohydrates, lipids, and proteins is normal to enhanced
in GLP-2-treated mice (64). Similarly, GLP-2-treated rats
exhibit enhanced absorption of glycine and galactose in association
with increased mucosal DNA and protein content (65).
Despite the suggestion that intracrebroventricular GLP-2 administration
inhibits food intake (66), GLP-2 treatment of normal
animals results in normal food intake, weight gain commensurate with
intestinal growth and an enhanced capacity for nutrient absorption
(64).
The finding that enteral nutrients regulate GLP-2 secretion suggests a
role for GLP-2 in mediating the trophic effect of nutrients on
maintaining the normal thickness of the mucosal epithelium. Rats
maintained on parenteral nutrition develop atrophy of the intestinal
epithelium in both the small and large intestine, possibly as a result
of reduced GLP-2 secretion. Intravenous coinfusion of GLP-2 and
parenteral nutrition prevented the development of mucosal atrophy in
the small but not the large bowel, illustrating the differential
regional sensitivity of the gut to the trophic effects of GLP-2
(62, 67). Consistent with these findings, GLP-2
significantly improved the endogenous intestinal adaptive response to
major small bowel resection in rats, with increased nutrient absorption
and reduced intestinal permeability observed in the GLP-2-treated
animals (68, 69).
The trophic and reparative effects of GLP-2 on the gut mucosa have also
been observed in the setting of experimental intestinal injury.
Following induction of indomethacin-induced intestinal inflammation,
GLP-2 significantly reduced intestinal disease activity scores and
cytokine expression, decreased bacterial sepsis, and reduced
mortality in mice with enteritis (70). Remarkably, GLP-2
was most effective in ameliorating disease activity when administered
as a pretreatment regimen before onset of indomethacin-induced
enteritis (70). GLP-2 also increased mucosal DNA content
and significantly reduced mortality in rats following vascular
ischemia-reperfusion injury of the small intestine (71).
The protective effects of GLP-2 in the gut have also been observed in
the large bowel as mice with dextran sulfate colitis exhibit reduced
parameters of disease activity, decreased intestinal interleukin
expression, and significantly reduced weight loss after GLP-2
administration (72). Similarly, GLP-2 significantly
reduced gross and microscopic mucosal damage and decreased cytokine
expression in rats with antigen-induced inflammatory bowel disease
(73).
The detection of GLP-2 receptor mRNA transcripts in the fetal and
neonatal rat intestine (74) raises the possibility that
GLP-2 may play a role in the development and maturation of the
gastrointestinal tract. Daily administration of h[Gly2]-GLP-2 to
neonatal rats enhanced stomach and small bowel weight and small bowel
length (74). Furthermore, iv infusion of GLP-2 decreased
proteolysis, reduced apoptosis, increased villus height, and was
trophic to the gastrointestinal tract of immature pigs
(75). Whether GLP-2 plays a role in growth and
differentiation of the developing fetal gut remains unclear.
|
Mechanisms underlying GLP-2 action: the GLP-2 receptor
|
|---|
The actions of GLP-2 in the gut are mediated by a distinct GLP-2
receptor, a recently cloned member of the glucagon/GLP-1 G
protein-coupled receptor superfamily (76). GLP-2R cDNAs
isolated from intestinal and hypothalamic cDNA libraries are identical
in sequence and encode a predicted receptor of 550 amino acids,
exhibiting considerable amino acid identity with the glucagon and
GLP-1 receptors. The GLP-2R gene was localized to human
chromosome 17p13.3, a chromosomal region not yet linked to inheritance
of familial intestinal diseases. Activation of GLP-2R signaling is
coupled to an increase in cAMP with an EC50 of
0.58 nM GLP-2. In contrast, structurally related
peptides such as glucagon, GLP-1, GIP, or exendin-4 do not
activate the GLP-2R even at 10-nM concentrations
(76). The intestinotrophic properties of GLP-2 derivatives
in mice in vivo correlate well with the relative activation
of GLP-2R signaling in transfected fibroblasts by these same peptides
in vitro (76, 77). Analysis of the activity of
alanine-substituted and both N- and C-terminally deleted GLP-2
molecules using the transfected GLP-2R expressed in fibroblasts
identified a number of amino acid substitutions in the GLP-2 molecule
that result in either diminished receptor binding and/or reduced
receptor activation in vitro (77).
The GLP-2R is expressed in a highly tissue-specific manner,
predominantly in the stomach, jejunum, ileum, and colon (76, 78). The results of Northern blotting, RNase protection, and
RT-PCR experiments are consistent with the presence of a single GLP-2R
transcript in the gastrointestinal tract and central nervous system of
rodents and humans (78). The GLP-2R has been localized to
subsets of enteroendocrine cells in the human gut. GLP-2R+ gut
endocrine cells also exhibit immunopositivity for either GIP,
serotonin, peptide YY, chromogranin, or GLP-1
(78). Although GLP-2 presumably exerts direct effects on
enteroendocrine cells expressing the GLP-2R, it seems likely that many
of the effects of GLP-2 on gastrointestinal target cells that do not
express the GLP-2R are indirect, resulting in modulation of gastric
motility, small bowel permeability, and both crypt cell proliferation
and apoptosis. Hence, one model that explains GLP-2 action suggests
that GLP-2 synthesized in and secreted from the small and large
intestine exerts many of its actions in an autocrine, paracrine, or
endocrine manner by stimulating the release of as yet unidentified
mediators from GLP-2R+ gut endocrine cells. It seems likely that these
GLP-2R+ enteroendocrine cells then release one or more factors that
mediate the pleiotropic biological actions of GLP-2 in the gut (Fig. 1).
The observations that GLP-2 inhibits enterocyte and crypt compartment
apoptosis following intestinal injury (70) prompted
analysis of the mechanisms coupling GLP-2R signaling to reduced cell
death. Remarkably, direct activation of GLP-2R signaling in transfected
baby hamster kidney fibroblasts expressing the GLP-2 receptor
(BHK-GLP-2R cells) confers resistance to cycloheximide-induced
apoptosis (79). GLP-2 reduced activation of caspase-8,
caspase-9, decreased cytochrome c release, and reduced caspase-3
cleavage, in a protein kinase A-independent manner. The
antiapoptotic actions of GLP-2 are not diminished by inhibitors of the
phosphatidyl inositol-3 kinase or mitogen-activated protein
kinase pathways (79). Furthermore, GLP-2 enhanced survival
and decreased intestinal apoptosis in tumor-bearing mice treated with
chemotherapy and reduced apoptosis and caspase activation in BHK-GLP-2R
cells treated with irinotecan in vitro (80).
These findings demonstrating a direct antiapoptotic effect of GLP-2 on
cells expressing a GLP-2 receptor, taken together with the
cytoprotective effects of GLP-2 in vivo on target cells that
do not seem to express the GLP-2 receptor (70, 72, 80)
suggest that GLP-2 inhibits cell death via both direct and indirect
signaling pathways.
|
Summary of current knowledge and unanswered questions
|
|---|
The available data demonstrate that GLP-2 regulates motility,
nutrient absorption, epithelial permeability, cell proliferation, and
apoptosis in the gastrointestinal tract. Whether one or more of these
actions will prove to be essential for normal gut physiology in the
absence of intestinal injury awaits the development of GLP-2
antagonists or rodent models of disrupted GLP-2 action. Similarly, the
actions of GLP-2 have been principally delineated in rodents and the
biological activities of GLP-2 in human subjects currently remain
unclear. Nevertheless, the strong conservation of GLP-2 and GLP-2R
sequences across species suggests that the physiological actions of
GLP-2 in rodents and humans are likely to be comparable. In this
regard, the results of a recent study of GLP-2 administration in human
subjects with short bowel syndrome demonstrated enhanced energy
absorption and increased crypt plus villus height in GLP-2-treated
patients (81). Given the expression of the GLP-2 receptor
in the central nervous system (76, 78), it seems likely
that GLP-2, like GLP-1, also subserves one or more
functions in the brain. Indeed, intracerebroventricular injection of
GLP-2 in the rat reduces food intake (66), raising the
possibility that GLP-2, perhaps like GLP-1, acts as a
central satiety factor. The multiple actions of GLP-2 that include
protection and restoration of the gut epithelium and enhancement of
nutrient absorption will likely stimulate clinical testing of the
therapeutic potential of this peptide in human diseases characterized
by injury and/or dysfunction of the gut epithelium. Whether GLP-2 will
ultimately prove therapeutically useful and safe for the treatment of
human gastrointestinal diseases requires careful assessment in properly
controlled clinical trials.
|
Footnotes
|
|---|
1 Studies from the Drucker laboratory are supported by an operating
grant from the Canadian Institute of Health Research and the Ontario
Research and Development Challenge Fund. 
2 Senior Scientist of
the Canadian Institute of Health Research, a consultant to NPS Allelix
Corp., and a party to a glucagon-like peptide 2-related licensing
agreement between the University of Toronto, the Toronto General
Hospital, and NPS Allelix Corp.
Received October 4, 2000.
Revised December 8, 2000.
Accepted December 27, 2000.
|
References
|
|---|
-
Drucker DJ. 1998 The glucagon-like peptides. Diabetes. 47:159–169.[Abstract]
-
Drucker DJ. 2001 The glucagon-like peptides. Endocrinology. 42:521–527.
-
Holst JJ. 1997 Enteroglucagon. Annu Rev Physiol. 59:257–291.[CrossRef][Medline]
-
Kieffer TJ, Habener JF. 1999 The glucagon-like
peptides. Endocr Rev. 20:876–913.[Abstract/Free Full Text]
-
Lund PK, Goodman RH, Dee PC, Habener JF. 1982 Pancreatic preproglucagon cDNA contains two glucagon-related coding
sequences arranged in tandem. Proc Natl Acad Sci USA. 79:345–349.[Abstract/Free Full Text]
-
Bell GI, Santerre RF, Mullenbach GT. 1983 Hamster
preproglucagon contains the sequence of glucagon and two related
peptides. Nature. 302:716–718.[CrossRef][Medline]
-
Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian
RC. 1983 Exon duplication and divergence in the human
preproglucagon gene. Nature. 304:368–371.[CrossRef][Medline]
-
Heinrich G, Gros P, Habener JF. 1984 Glucagon gene
sequence: four of the six exons encode separate functional domains of
rat pre-proglucagon. J Biol Chem. 259:14082–14087.[Abstract/Free Full Text]
-
Heinrich G, Gros P, Lund PK, Bentley RC, Habener
JF. 1984 Pre-proglucagon messenger ribonucleic acid: nucleotide
and encoded amino acid sequences of the rat pancreatic complementary
deoxyribonucleic acid. Endocrinology. 115:2176–2181.[Abstract/Free Full Text]
-
White JW, Saunders GF. 1986 Structure of the human
glucagon gene. Nucleic Acids Res. 14:4719–4730.[Abstract/Free Full Text]
-
Irwin DM, Wong J. 1995 Trout and chicken
proglucagon: alternative splicing generates mRNA transcripts encoding
glucagon-like peptide 2. Mol Endocrinol. 9:267–277.[Abstract/Free Full Text]
-
Chen YE, Drucker DJ. 1997 Tissue-specific
expression of unique mRNAs that encode proglucagon-derived peptides or
exendin 4 in the lizard. J Biol Chem. 272:4108–4115.[Abstract/Free Full Text]
-
Dhanvantari S, Seidah NG, Brubaker PL. 1996 Role of
prohormone convertases in the tissue-specific processing of
proglucagon. Mol Endocrinol. 10:342–355.[Abstract/Free Full Text]
-
Orskov C, Buhl T, Rabenhoj L, Kofod H, Holst JJ. 1989 Carboxypeptidase-B-like processing of the C-terminus of
glucagon-like peptide-2 in pig and human small intestine. FEBS Lett. 247:193–196.[CrossRef][Medline]
-
Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L,
Holst JJ. 2000 Structure, measurement, and secretion of human
glucagon-like peptide-2. Peptides. 21:73–80.[CrossRef][Medline]
-
Hoosein NM, Gurd RS. 1984 Human glucagon-like
peptides 1 and 2 activate rat brain adenylate cyclase. FEBS Lett. 178:83–86.[CrossRef][Medline]
-
Lund PK, Ulshen MH, Roundtree DB, Selub SE, Buchan
AM. 1990 Molecular biology of gastrointestinal peptides and growth
factors: relevance to intestinal adaptation. Digestion. 46:66–73.
-
Bloom SR, Polak JM. 1982 The hormonal pattern of
intestinal adaptation [a major role for enteroglucagon]. Scand J
Gastroenterol. 17:93–103.
-
Besterman HS, Adrian TE, Mallinson CN, et al. 1982 Gut hormone release after intestinal resection. Gut. 23:854–861.[Abstract/Free Full Text]
-
Sagor GR, Ghatei MA, Al-Mukhtar MYT, Wright NA, Bloom
SR. 1983 Evidence for a humoral mechanism after small intestinal
resection. Gastroenterology. 84:902–906.[Medline]
-
Miazza BM, Al-Mukhtar MYT, Salmeron M, et al. 1985 Hyperenteroglucagonaemia and small intestinal mucosal growth after
colonic perfusion of glucose in rats. Gut. 26:518–524.[Abstract/Free Full Text]
-
Taylor RG, Fuller PJ. 1994 Humoral regulation of
intestinal adaptation. Baillieres Clin Endocrinol Metab. 8:165–183.[CrossRef][Medline]
-
Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling
RH. 1971 Endocrine tumour in kidney affecting small bowel
structure, motility, and absorptive function. Gut. 12:773–782.[Abstract/Free Full Text]
-
Stevens FM, Flanagan RW, O’Gorman D, Buchanan KD. 1984 Glucagonoma syndrome demonstrating giant duodenal villi. Gut. 25:784–791.[Abstract/Free Full Text]
-
Drucker DJ, Ehrlich P, Asa SL, Brubaker PL. 1996 Induction of intestinal epithelial proliferation by glucagon-like
peptide 2. Proc Natl Acad Sci USA. 93:7911–7916.[Abstract/Free Full Text]
-
Drucker DJ, Asa S. 1988 Glucagon gene expression in
vertebrate brain. J Biol Chem. 263:13475–13478.[Abstract/Free Full Text]
-
Drucker DJ, Brubaker PL. 1989 Proglucagon gene
expression is regulated by a cyclic AMP-dependent pathway in rat
intestine. Proc Natl Acad Sci USA. 86:3953–3957.[Abstract/Free Full Text]
-
Novak U, Wilks A, Buell G, McEwen S. 1987 Identical
mRNA for preproglucagon in pancreas and gut. Eur J Biochem. 164:553–558.[Medline]
-
Orskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Poulsen
SS, Nielsen OV. 1986 Glucagon-like peptides GLP-1 and GLP-2,
predicted products of the glucagon gene, are secreted separately from
pig small intestine but not pancreas. Endocrinology. 119:1467–1475.[Abstract/Free Full Text]
-
Rountree DB, Ulshen MH, Selub S, et al. 1992 Nutrient-independent increases in proglucagon and ornithine
decarboxylase messenger RNAs after jejunoileal resection. Gastroenterology. 103:462–468.[Medline]
-
Hoyt EC, Lund PK, Winesett DE, et al. 1996 Effects
of fasting, refeeding and intraluminal triglyceride on proglucagon
expression in jejunum and ileum. Diabetes. 45:434–439.[Abstract]
-
Reimer RA, McBurney MI. 1996 Dietary fiber
modulates intestinal proglucagon messenger ribonucleic acid and
postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology. 137:3948–3956.[Abstract]
-
Tappenden KA, Thomson AB, Wild GE, McBurney MI. 1996 Short-chain fatty acids increase proglucagon and ornithine
decarboxylase messenger RNAs after intestinal resection in rats. J
Parenter Enteral Nutr. 20:357–362.[Abstract/Free Full Text]
-
Orskov C, Holst JJ. 1987 Radio-immunoassays for
glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab
Invest. 47:165–174.[Medline]
-
Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai C-H,
Drucker DJ. 1997 Circulating and tissue forms of the intestinal
growth factor, glucagon-like peptide 2. Endocrinology. 138:4837–4843.[Abstract/Free Full Text]
-
Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. 1999 Secretion of the intestinotropic hormone glucagon-like peptide 2 is
differentially regulated by nutrients in humans. Gastroenterology. 117:99–105.[CrossRef][Medline]
-
Burrin DG, Stoll B, Jiang R, et al. 2000 Minimal
enteral nutrient requirements for intestinal growth in neonatal
piglets: how much is enough? Am J Clin Nutr. 71:1603–1610.[Abstract/Free Full Text]
-
Thulesen J, Hartmann B, Nielsen C, Holst JJ, Poulsen
SS. 1999 Diabetic intestinal growth adaptation and glucagon-like
peptide 2 in the rat: effects of dietary fibre. Gut. 45:672–678.[Abstract/Free Full Text]
-
Fuller PJ, Beveridge DJ, Taylor RG. 1993 Ileal
proglucagon gene expression in the rat: characterization in intestinal
adaptation using in situ hybridization. Gastroenterology. 104:459–466.[Medline]
-
Taylor RG, Verity K, Fuller PJ. 1990 Ileal glucagon
gene expression: ontogeny and response to massive small bowel
resection. Gastroenterology. 99:724–729.[Medline]
-
Taylor RG, Beveridge DJ, Fuller PJ. 1992 Expression
of ileal glucagon and peptide tyrosine-tyrosine genes. Response to
inhibition of polyamine synthesis in the presence of massive
small-bowel resection. Biochem J. 286:737–741.
-
Ulshen MH, Hoyt EC, Fuller CR, Ghatei MA, Bloom SR, Lund
PK. 1996 Increased ileal proglucagon expression after jejunectomy
is not suppressed by inhibition of bowel growth. Dig Dis Sci. 41:677–683.[CrossRef][Medline]
-
Orskov C, Andreasen J, Holst JJ. 1992 All products
of proglucagon are elevated in plasma from uremic patients. J Clin
Endocrinol Metab. 74:379–384.[Abstract]
-
Ruiz-Grande C, Pintado J, Alarcon C, Castilla C,
Valverde I, Lopez-Novoa JM. 1990 Renal catabolism of human
glucagon-like peptides 1 and 2. Can J Physiol Pharmacol. 68:1568–1573.[Medline]
-
Tavares W, Drucker DJ, Brubaker PL. 1999 Enzymatic
and renal-dependent catabolism of the intestinotropic hormone
glucagon-like peptide-2 in the rat. Am J Physiol.
278:E134–E139.
-
Hartmann B, Harr MB, Jeppesen PB, et al. 2000 In vivo and in vitro degradation of glucagon-like
peptide-2 in humans. J Clin Endocrinol Metab. 85:2884–2888.[Abstract/Free Full Text]
-
Drucker DJ, Shi Q, Crivici A, et al. 1997 Regulation of the biological activity of glucagon-like peptide 2 by
dipeptidyl peptidase IV. Nat Biotechnol. 15:673–677.[CrossRef][Medline]
-
Kieffer TJ, McIntosh CHS, Pederson RA. 1995 Degradation of glucosedependent insulinotropic polypeptide and
truncated glucagon-like peptide 1 in vitro and in
vivo by dipeptidyl peptidase IV. Endocrinology. 136:3585–3596.[Abstract]
-
De Meester I, Korom S, Van Damme J, Scharpe S. 1999 CD26, let it cut or cut it down. Immunol Today. 20:367–375.[CrossRef][Medline]
-
Hartmann B, Thulesen J, Kissow H, et al. 2000 Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect
of glucagon-like peptide-2 in rats and mice. Endocrinology. 141:4013–4020.[Abstract/Free Full Text]
-
Fischer KD, Dhanvantari S, Drucker DJ, Brubaker PL. 1997 Intestinal growth is associated with elevated levels of
glucagon-like peptide-2 in diabetic rats. Am J Physiol.
273:E815–E820.
-
Xiao Q, Boushey RP, Cino M, Drucker DJ, Brubaker
PL. 2000 Circulating levels of glucagon-like peptide-2 in human
subjects with inflammatory bowel disease. Am J Physiol.
278:R1057–R1063.
-
Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst
JJ, Mortensen PB. 1999 Impaired meal-stimulated glucagon-like
peptide-2 response in ileal resected short bowel patients with
intestinal failure. Gut. 45:559–563.[Abstract/Free Full Text]
-
Jeppesen PB, Hartmann B, Thulesen J, et al. 2000 Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum
resected short bowel patients with a preserved colon. Gut. 47:370–376.[Abstract/Free Full Text]
-
Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst
JJ. 1999 Inhibition of sham feeding-stimulated human gastric acid
secretion by glucagon-like peptide-2. J Clin Endocrinol Metab. 84:2513–2517.[Abstract/Free Full Text]
-
Wojdemann M, Wettergren A, Hartmann B, Holst JJ. 1998 Glucagon-like peptide-2 inhibits centrally induced antral motility
in pigs. Scand J Gastroenterol. 33:828–832.[CrossRef][Medline]
-
Cheeseman CI, Tsang R. 1996 The effect of gastric
inhibitory polypeptide and glucagon like peptides on intestinal hexose
transport. Am J Physiol Gastrointest Liver Physiol.
271:G477–G482.
-
Cheeseman CI. 1997 Up-regulation of SGLT-1
transport activity in rat jejunum induced by GLP-2 infusion in
vivo. Am J Physiol. 273:R1965–R1971.
-
Benjamin MA, McKay DM, Yang P-C, Perdue MH. 2000 Glucagon-like peptide-2 enhances epithelial barrier function of both
transcellular and paracellular pathways in the mouse. Gut. 47:112–119.[Abstract/Free Full Text]
-
Tsai C-H, Hill M, Asa SL, Brubaker PL, Drucker DJ. 1997 Intestinal growth-promoting properties of glucagon-like peptide 2
in mice. Am J Physiol. 273:E77–E84.
-
Tsai C-H, Hill M, Drucker DJ. 1997 Biological
determinants of intestinotrophic properties of GLP-2 in
vivo. Am J Physiol. 272:G662–G668.
-
Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam
A. 1997 Prevention of parenteral nutrition-induced gut hyoplasia
by coinfusion of glucagon-like peptide-2. Am J Physiol.
273:G559–G563.
-
Drucker DJ, Deforest L, Brubaker PL. 1997 Intestinal response to growth factors administered alone or in
combination with h[Gly2]-glucagon-like peptide 2. Am J Physiol.
273:G1252–G1262.
-
Brubaker PL, Izzo A, Hill M, Drucker DJ. 1997 Intestinal function in mice with small bowel growth induced by
glucagon-like peptide-2. Am J Physiol. 272:E1050–E1058.
-
Kato Y, Yu D, Schwartz MZ. 1999 Glucagon-like
peptide-2 enhances small intestinal absorptive function and mucosal
mass in vivo. J Pediatr Surg. 34:18–20.[CrossRef][Medline]
-
Tang-Christensen M, Larsen PJ, Thulesen J, Romer J,
Vrang N. 2000 The proglucagon-derived peptide, glucagon-like
peptide-2, is a neurotransmitter involved in the regulation of food
intake. Nat Med. 6:802–807.[CrossRef][Medline]
-
Kitchen PA, Fitzgerald AJ, Goodlad RA, et al. 2000 Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-
related homeobox protein-2 gene expression. Am J Physiol
Gastrointest Liver Physiol. 278:G425–G428.
-
Scott RB, Kirk D, MacNaughton WK, Meddings JB. 1998 GLP-2 augments the adaptive response to massive intestinal resection in
rat. Am J Physiol. 275:G911–G921.
-
Sigalet DL, Martin GR. 2000 Hormonal therapy for
short bowel syndrome. J Pediatr Surg. 35:360–363; discussion,
364.[CrossRef][Medline]
-
Boushey RP, Yusta B, Drucker DJ. 1999 Glucagon-like
peptide 2 decreases mortality and reduces the severity of
indomethacin-induced murine enteritis. Am J Physiol.
277:E937–E947.
-
Prasad R, Alavi K, Schwartz MZ. 2000 Glucagon-like
peptide-2 analogue enhances intestinal mucosal mass after ischemia and
reperfusion. J Pediatr Surg. 35:357–359.[CrossRef][Medline]
-
Drucker DJ, Yusta B, Boushey RP, Deforest L, Brubaker
PL. 1999 Human [Gly2]-GLP-2 reduces the severity of colonic
injury in a murine model of experimental colitis. Am J Physiol.
276:G79–G91.
-
Alavi K, Schwartz MZ, Palazzo JP, Prasad R. 2000 Treatment of inflammatory bowel disease in a rodent model with the
intestinal growth factor glucagon-like peptide-2. J Pediatr Surg. 35:847–851.[CrossRef][Medline]
-
Lovshin J, Yusta B, Iliopoulos I, et al. 2000 Ontogeny of the glucagon-like peptide-2 receptor axis in the developing
rat intestine. Endocrinology. 141:4194–4201.[Abstract/Free Full Text]
-
Burrin DG, Stoll B, Jiang R, et al. 2000 GLP-2
stimulates intestinal growth in premature TPN-fed pigs by suppressing
proteolysis and apoptosis. Am J Physiol Gastrointest Liver
Physiol. 279:G1249–G1256.
-
Munroe DG, Gupta AK, Kooshesh P, et al. 1999 Prototypic G protein-coupled receptor for the intestinotrophic factor
glucagon-like peptide 2. Proc Natl Acad Sci USA. 96:1569–1573.[Abstract/Free Full Text]
-
DaCambra MP, Yusta B, Sumner-Smith M, Crivici A, Drucker
DJ, Brubaker PL. 2000 Structural determinants for activity of
glucagon-like peptide-2. Biochemistry. 39:8888–8894.[CrossRef][Medline]
-
Yusta B, Huang L, Munroe D, et al. 2000 Enteroendocrine localization of GLP-2 receptor expression. Gastroenterology. 119:744–755.[CrossRef][Medline]
-
Yusta B, Boushey RP, Drucker DJ. 2000 The
glucagon-like peptide-2 receptor mediates direct inhibition of cellular
apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem. 275:35345–35352.[Abstract/Free Full Text]
-
Boushey RP, Yusta B, Drucker DJ. 2001 Glucagon-like
peptide-2 (GLP-2) reduces chemotherapy-associated mortality and
enhances cell survival in cells expressing a transfected GLP-2
receptor. Cancer Res. 61:687–693.[Abstract/Free Full Text]
-
Jeppesen PB, Hartmann B, Thulesen J, et al.
Treatment of short bowel patients with glucagon-like peptide-2 (GLP-2),
a newly discovered intestinotrophic, anti-secretory, and
transit-modulating peptide. Gastroenterology. In press.
This article has been cited by other articles:
|
|
|
|
 
M. Metwally, S. Amer, T.C. Li, and W.L. Ledger
An RCT of metformin versus orlistat for the management of obese anovulatory women
Hum. Reprod.,
April 1, 2009;
24(4):
966 - 975.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Ozer, J. J. Holst, N. Duman, A. Kumral, and H. Ozkan
The Relationship between Glucagon-Like Peptide 2 and Feeding Intolerance in Preterm Infants
J Trop Pediatr,
May 22, 2008;
(2008)
fmn033v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Henriksen
The Gut Feeling of Bone Remodeling
IBMS BoneKEy,
November 1, 2005;
2(11):
16 - 23.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dey, G. M. Lipkind, Y. Rouille, C. Norrbom, J. Stein, C. Zhang, R. Carroll, and D. F. Steiner
Significance of Prohormone Convertase 2, PC2, Mediated Initial Cleavage at the Proglucagon Interdomain Site, Lys70-Arg71, to Generate Glucagon
Endocrinology,
February 1, 2005;
146(2):
713 - 727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lovshin, Q. Huang, R. Seaberg, P. L. Brubaker, and D. J. Drucker
Extrahypothalamic Expression of the Glucagon-Like Peptide-2 Receptor Is Coupled to Reduction of Glutamate-Induced Cell Death in Cultured Hippocampal Cells
Endocrinology,
July 1, 2004;
145(7):
3495 - 3506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ramsanahie, M. S. Duxbury, T. C. Grikscheit, A. Perez, D. B. Rhoads, J. Gardner-Thorpe, J. Ogilvie, S. W. Ashley, J. P. Vacanti, and E. E. Whang
Effect of GLP-2 on mucosal morphology and SGLT1 expression in tissue-engineered neointestine
Am J Physiol Gastrointest Liver Physiol,
December 1, 2003;
285(6):
G1345 - G1352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gros, X. You, L. L. Baggio, M. G. Kabir, A. M. Sadi, I. N. Mungrue, T. G. Parker, Q. Huang, D. J. Drucker, and M. Husain
Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor
Endocrinology,
June 1, 2003;
144(6):
2242 - 2252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M. Petersen, B. Hartmann, J. J. Holst, I. Le Huerou-Luron, C. R. Bjornvad, and P. T. Sangild
Introduction of Enteral Food Increases Plasma GLP-2 and Decreases GLP-2 Receptor mRNA Abundance during Pig Development
J. Nutr.,
June 1, 2003;
133(6):
1781 - 1786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Cao, G. Flock, C. Choi, D. M. Irwin, and D. J. Drucker
Aberrant Regulation of Human Intestinal Proglucagon Gene Expression in the NCI-H716 Cell Line
Endocrinology,
May 1, 2003;
144(5):
2025 - 2033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Pharmacol. Rev.,
March 1, 2003;
55(1):
167 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Drucker
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Mol. Endocrinol.,
February 1, 2003;
17(2):
161 - 171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. K.Y. Trinh, K. Zhang, M. Hossain, P. L. Brubaker, and D. J. Drucker
Pax-6 Activates Endogenous Proglucagon Gene Expression in the Rodent Gastrointestinal Epithelium
Diabetes,
February 1, 2003;
52(2):
425 - 433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, T. Hansotia, B. Yusta, F. Ris, P. A. Halban, and D. J. Drucker
Glucagon-like Peptide-1 Receptor Signaling Modulates beta Cell Apoptosis
J. Biol. Chem.,
January 3, 2003;
278(1):
471 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhu, A. Zhou, A. Dey, C. Norrbom, R. Carroll, C. Zhang, V. Laurent, I. Lindberg, R. Ugleholdt, J. J. Holst, et al.
Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects
PNAS,
August 6, 2002;
99(16):
10293 - 10298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Yusta, J. Estall, and D. J. Drucker
Glucagon-like Peptide-2 Receptor Activation Engages Bad and Glycogen Synthase Kinase-3 in a Protein Kinase A-dependent Manner and Prevents Apoptosis following Inhibition of Phosphatidylinositol 3-Kinase
J. Biol. Chem.,
July 5, 2002;
277(28):
24896 - 24906.
[Abstract]
[Full Text]
[PDF]
|
|
|
Top
Abstract
Introduction
